AVP and Cirrhosis: In patients with persistently low effective circulating volume (eg, chronic HF with reduced ejection fraction, advanced cirrhosis), sustained AVP secretion activates vasopressin receptor 1A, promoting myocardial remodeling and fibrosis, leading to increased morbidity and mortality (19, 47).